VivoSeq
Metabolic & Endocrine

Fucosidosis

2

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Fucosidosis is an early-stage landscape with 2 programs across 1 company. The most active players are Akero Therapeutics. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Akero Therapeutics logo

Akero Therapeutics

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved2

Cyclophosphamide

Baxter Healthcare Corporation

Busulfan

Akero Therapeutics

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)